Stockscreener 앱 받기
4.535
1.58%
0.095
전일 마감가:
$4.44
열려 있는:
$4.34
하루 거래량:
228.14K
Relative Volume:
0.49
시가총액:
$80.01M
수익:
-
순이익/손실:
$-30.54M
주가수익비율:
-2.9258
EPS:
-1.55
순현금흐름:
$-18.30M
1주 성능:
-4.45%
1개월 성능:
-2.38%
6개월 성능:
+591.61%
1년 성능:
+839.78%
1일 변동 폭
$4.32
$4.59
1주일 범위
$4.32
$5.09
52주 변동 폭
$0.4139
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
명칭
Unicycive Therapeutics Inc
전화
650-384-0642
주소
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
UNCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
4.5299 | 78.42M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.55 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
631.32 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
426.50 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
841.11 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.03 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-21 | 개시 | Guggenheim | Buy |
| 2024-04-04 | 개시 | Piper Sandler | Overweight |
Unicycive Therapeutics Inc 주식(UNCY)의 최신 뉴스
Why Unicycive Therapeutics Inc. stock remains resilientLong Setup & Fast Entry and Exit Trade Plans - newser.com
Can Unicycive Therapeutics Inc. stock sustain institutional interestProduct Launch & Stepwise Trade Signal Implementation - newser.com
How Unicycive Therapeutics Inc. stock compares to growth peers2025 Technical Overview & Low Drawdown Investment Strategies - newser.com
Live market analysis of Unicycive Therapeutics Inc.Weekly Earnings Recap & Verified Momentum Stock Alerts - newser.com
What catalysts could drive Unicycive Therapeutics Inc. stock higherJuly 2025 Highlights & Reliable Breakout Forecasts - newser.com
Unicycive Therapeutics, Inc. (UNCY) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Unicycive Therapeutics price target raised to $22 from $9 at H.C. Wainwright - MSN
How rising interest rates impact Unicycive Therapeutics Inc. stockWeekly Stock Report & Fast Moving Trade Plans - newser.com
Sentiment analysis tools applied to Unicycive Therapeutics Inc.2025 Earnings Surprises & Verified Entry Point Signals - newser.com
Unicycive Therapeutics to Participate in a Fireside Chat at - GlobeNewswire
What moving averages say about Unicycive Therapeutics Inc.2025 Price Momentum & Risk Controlled Stock Alerts - newser.com
Will Unicycive Therapeutics Inc. stock beat EPS estimates2025 Winners & Losers & Verified Swing Trading Watchlists - newser.com
Can Unicycive Therapeutics Inc. stock hit analyst price targetsJuly 2025 Selloffs & Expert-Curated Trade Recommendations - newser.com
Unicycive Therapeutics, Inc. (UNCY) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Is Unicycive Therapeutics Inc. meeting your algorithmic filter criteria2025 Key Lessons & Long-Term Capital Growth Strategies - newser.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect - ACCESS Newswire
Does Unicycive Therapeutics Inc. show high probability of reboundJuly 2025 Sector Moves & Reliable Breakout Forecasts - newser.com
Identifying reversal signals in Unicycive Therapeutics Inc.2025 Geopolitical Influence & Consistent Profit Trade Alerts - newser.com
Unicycive Therapeutics (NASDAQ:UNCY) Raised to Hold at Wall Street Zen - MarketBeat
HC Wainwright Analysts Increase Earnings Estimates for UNCY - MarketBeat
Unicycive Leaders Sued for Touting Kidney Treatment’s Prospects - Bloomberg Law News
Unicycive Therapeutics (NASDAQ:UNCY) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat
UNICYCIVE ALERT: Bragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. ... - Bluefield Daily Telegraph
UNICYCIVE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Unicycive Therapeutics - Nasdaq
Custom strategy builders for tracking Unicycive Therapeutics Inc.Trade Entry Report & Long-Term Investment Growth Plans - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), United Therapeutics (UTHR) and Unicycive Therapeutics (UNCY) - The Globe and Mail
How Unicycive Therapeutics Inc. stock performs in interest rate cyclesJuly 2025 Short Interest & AI Powered Buy/Sell Recommendations - newser.com
Optimistic Buy Rating for Unicycive Therapeutics Driven by Promising Clinical Progress and Financial Stability - TipRanks
Analyzing net buyer seller activity in Unicycive Therapeutics Inc.2025 Geopolitical Influence & Growth Focused Entry Reports - newser.com
Will a bounce in Unicycive Therapeutics Inc. offer an exit2025 Price Action Summary & Step-by-Step Swing Trade Plans - newser.com
Guggenheim Sticks to Its Buy Rating for Unicycive Therapeutics (UNCY) - The Globe and Mail
Benchmark Co. Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Connect - ACCESS Newswire
Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference - The Manila Times
Unicycive Therapeutics to Present New Data for Oxylanthanum Carbonate at ASN Kidney Week 2025 - Quiver Quantitative
Unicycive (NASDAQ: UNCY) to present OLC data: 7x lower pill volume, 2x fewer pills at ASN - Stock Titan
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alkermes (ALKS), Arcutis Biotherapeutics (ARQT) and Unicycive Therapeutics (UNCY) - The Globe and Mail
Unicycive Therapeutics Inc (UNCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.35%
0.35%
자본화:
|
볼륨(24시간):